Skip to main content
. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176

Table 1.

Clinical-pathological characteristics of B490 study (n = 191) compared to the cohort considered in the current study with available RNA (n = 123) that was analyzed for gene expression.

Variable Study Population Clinical Trial Article
(n = 191)
Samples with Available RNA
(n = 123)
Randomization arm Cetuximab + cisplatin
Cetuximab + cisplatin + paclitaxel
100 (52%)
91 (48%)
61 (50%)
62 (50%)
Age (years) Median
Range
63
33–83
62
33–83
Sex, n (%) Female
Male
42 (22%)
149 (78%)
27 (22%)
96 (78%)
ECOG PS, n (%) 0
1
97 (51%)
94 (49%)
74 (60%)
49 (40%)
Primary tumor site, n (%) Oropharynx
Other
70 (37%)
121 (63%)
49 (40%)
74 (60%)
HPV, n (%)
(oropharynx only)
Not tested
HPV-negative
HPV-positive
41 (59%)
16 (23%)
13 (19%)
35 (71%)
6 (12%)
8 (16%)
Site of recurrence, n (%) Missing
Local recurrence
Locoregional recurrence
Metastasis
Metastasis/local/regional recurrence
Regional recurrence
3 (2%)
27 (14%)
42 (22%)
59 (31%)
49 (26%)

11 (6%)
1 (1%)
14 (11%)
26 (21%)
37 (30%)
38 (31%)

7 (6%)